Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 7
2007 5
2008 2
2009 5
2010 3
2011 6
2012 7
2013 3
2014 1
2015 1
2016 3
2017 5
2018 6
2019 9
2020 10
2021 7
2022 4
2023 1
2024 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Results by year

Filters applied: . Clear all
Page 1
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators. Flaherty KR, et al. N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29. N Engl J Med. 2019. PMID: 31566307 Clinical Trial.
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; INBUILD trial investigators. Wells AU, et al. Lancet Respir Med. 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5. Lancet Respir Med. 2020. PMID: 32145830 Clinical Trial.
Integration and Application of Clinical Practice Guidelines for the Diagnosis of Idiopathic Pulmonary Fibrosis and Fibrotic Hypersensitivity Pneumonitis.
Marinescu DC, Raghu G, Remy-Jardin M, Travis WD, Adegunsoye A, Beasley MB, Chung JH, Churg A, Cottin V, Egashira R, Fernández Pérez ER, Inoue Y, Johannson KA, Kazerooni EA, Khor YH, Lynch DA, Müller NL, Myers JL, Nicholson AG, Rajan S, Saito-Koyama R, Troy L, Walsh SLF, Wells AU, Wijsenbeek MS, Wright JL, Ryerson CJ. Marinescu DC, et al. Among authors: fernandez perez er. Chest. 2022 Sep;162(3):614-629. doi: 10.1016/j.chest.2022.06.013. Epub 2022 Jun 20. Chest. 2022. PMID: 35738345 Review.
Eosinophilic lung diseases.
Fernández Pérez ER, Olson AL, Frankel SK. Fernández Pérez ER, et al. Med Clin North Am. 2011 Nov;95(6):1163-87. doi: 10.1016/j.mcna.2011.08.006. Med Clin North Am. 2011. PMID: 22032433 Review.
Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial.
Richeldi L, Fernández Pérez ER, Costabel U, Albera C, Lederer DJ, Flaherty KR, Ettinger N, Perez R, Scholand MB, Goldin J, Peony Yu KH, Neff T, Porter S, Zhong M, Gorina E, Kouchakji E, Raghu G. Richeldi L, et al. Among authors: fernandez perez er. Lancet Respir Med. 2020 Jan;8(1):25-33. doi: 10.1016/S2213-2600(19)30262-0. Epub 2019 Sep 28. Lancet Respir Med. 2020. PMID: 31575509 Clinical Trial.
Pamrevlumab for Idiopathic Pulmonary Fibrosis: The ZEPHYRUS-1 Randomized Clinical Trial.
Raghu G, Richeldi L, Fernández Pérez ER, De Salvo MC, Silva RS, Song JW, Ogura T, Xu ZJ, Belloli EA, Zhang X, Seid LL, Poole L; ZEPHYRUS-1 Study Investigators. Raghu G, et al. Among authors: fernandez perez er. JAMA. 2024 Aug 6;332(5):380-389. doi: 10.1001/jama.2024.8693. JAMA. 2024. PMID: 38762797 Free PMC article. Clinical Trial.
Sepsis during pregnancy.
Fernández-Pérez ER, Salman S, Pendem S, Farmer JC. Fernández-Pérez ER, et al. Crit Care Med. 2005 Oct;33(10 Suppl):S286-93. doi: 10.1097/01.ccm.0000182479.63108.cd. Crit Care Med. 2005. PMID: 16215349 Review.
Approach to diagnosing and managing granulomatous-lymphocytic interstitial lung disease.
Galant-Swafford J, Catanzaro J, Achcar RD, Cool C, Koelsch T, Bang TJ, Lynch DA, Alam R, Katial RK, Fernández Pérez ER. Galant-Swafford J, et al. Among authors: fernandez perez er. EClinicalMedicine. 2024 Jul 26;75:102749. doi: 10.1016/j.eclinm.2024.102749. eCollection 2024 Sep. EClinicalMedicine. 2024. PMID: 39170934 Free PMC article. Review.
82 results